EP3661515B1 - Novel braf inhibitors and use thereof for treatment of cutaneous reactions - Google Patents

Novel braf inhibitors and use thereof for treatment of cutaneous reactions Download PDF

Info

Publication number
EP3661515B1
EP3661515B1 EP18841422.1A EP18841422A EP3661515B1 EP 3661515 B1 EP3661515 B1 EP 3661515B1 EP 18841422 A EP18841422 A EP 18841422A EP 3661515 B1 EP3661515 B1 EP 3661515B1
Authority
EP
European Patent Office
Prior art keywords
compound
pharmaceutical composition
formula
erk
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18841422.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3661515A2 (en
EP3661515A4 (en
Inventor
Noa Shelach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lutris Pharma Ltd
Original Assignee
Lutris Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lutris Pharma Ltd filed Critical Lutris Pharma Ltd
Priority to HRP20220609TT priority Critical patent/HRP20220609T1/hr
Priority to SI201830670T priority patent/SI3661515T1/sl
Publication of EP3661515A2 publication Critical patent/EP3661515A2/en
Publication of EP3661515A4 publication Critical patent/EP3661515A4/en
Application granted granted Critical
Publication of EP3661515B1 publication Critical patent/EP3661515B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • B-Raf serine/threonine-protein kinase B-Raf
  • EGFR Epidermal Growth Factor Receptor
  • EGFR antagonists such as monoclonal antibodies (e.g., cetuximab, panitumumab) and small molecule tyrosine kinase inhibitors (e.g. gefitinib, erlotinib, lapatinib) are used for treating many EGFR-mediated cancers. While these EGFR antagonists are useful for treating cancer, they are also associated with severe side effects. One such adverse effect of EGFR antagonists is cutaneous reactions.
  • Cutaneous adverse reactions to EGFR inhibitors include acneiform (papulopustular) rash, abnormal scalp, facial hair and/or eyelash growth, paronychia with or without pyogenic granulomas and telangiectasia.
  • kinases such as phosphatidylinositol-3-kinases (PI 3-kinases), mitogen-activated protein kinases (MAPK), and kinases upstream of MAPK such as MEK and MKK, act as downstream effectors of EGFR and many other receptor tyrosine kinases and are involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking.
  • Therapeutic agents that target these pathways are also used in the treatment of a number of proliferative diseases, such as melanoma, lung cancer, colorectal cancer, brain cancer, multiple myeloma, pancreatic cancer and neurofibromatosis.
  • Exemplary therapeutic agents that target these pathways include kinase inhibitors such as Trametinib and Cobimetinib.
  • inhibitors of these kinases are also associated with adverse side effects.
  • cutaneous adverse events caused by MEK inhibitors have been reported, and include acneiform (papulopustular) rash, abnormal scalp, facial hair and/or eyelash growth, paronychia with or without pyogenic granulomas and telangiectasia.
  • BRaf is a protein kinase involved in the regulation of the mitogen activated protein kinase (MAPK) signaling pathway. Mutations in BRaf can induce constitutive signaling through the MAPK pathway which may result in uncontrolled cell proliferation.
  • MAPK mitogen activated protein kinase
  • Use of BRaf inhibitors has been demonstrated to be associated with inhibition of MAPK signaling, as can be determined by reduction in levels of phosphorylated ERK, which is the downstream effector of BRaf.
  • BRaf inhibitors can paradoxically induce an opposite effect of activating MAPK signaling in BRaf wild-type cells (as determined by increased levels of phosphorylated ERK).
  • the underlying mechanisms of paradoxical MAPK activation have been attributed to dimerization of wild-type BRaf and c-Raf and transactivation of the non-inhibited Raf protein leading to subsequent MAPK pathway activation.
  • WO2017154001 discloses compositions comprising BRaf inhibitors and uses thereof for treating and/or preventing by topical or systemic administration cutaneous conditions caused by treatment with EGFR inhibitors and/or PI3K inhibitors.
  • US8557830 comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions.
  • the compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein.
  • the invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds.
  • WO2015171833 relates to methods for treating a wound are provided herein. Such methods include a step of contacting the wound with an effective amount of a BRAF inhibitor.
  • BRAF inhibitors may be part of a pharmaceutical composition.
  • the pharmaceutical composition may include an effective amount of a BRAF inhibitor and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is a topical agent comprising an ointment, cream liquid, gel, hydrogel, or a spray.
  • a BRAF inhibitor or a pharmaceutical composition thereof may be part of wound dressing for use in treating a wound. In this case, the wound dressing may be impregnated or coated with the BRAF inhibitor or pharmaceutical composition thereof.
  • WO2007076092 comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions.
  • the compounds have Formula (I) wherein R ⁇ 1> is Formula (II), (III) or (IV) and A ⁇ 1>, A ⁇ 2>, A ⁇ 3>, A ⁇ 4>, X, Z, Z', R ⁇ 1>, R ⁇ 2>, R ⁇ 3>, R ⁇ 4>, R ⁇ 5> and R ⁇ 6> are defined herein.
  • the invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds.
  • ADRIAN L. SMITH ET AL relates to "Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline", JOURNAL OF MEDICINAL CHEMISTRY, (20091022), vol. 52, no. 20, doi:10.1021/jm901081g, ISSN 0022-2623, pages 6189 - 6192 .
  • XIAOLUN WANG ET AL relates to "Conformation-Specific Effects of Raf Kinase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, (20120913), vol. 55, no. 17, doi: 10.1021/jm300613w, ISSN 0022-2623, pages 7332 - 7341 .
  • J. CARNAHAN ET AL relates to "Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth", MOLECULAR CANCER THERAPEUTICS, US, (20100727), vol. 9, no. 8, doi: 10.1158/1535-7163.MCT-10-0181, ISSN 1535-7163, pages 2399-2410 .
  • Josette Carnahan relates to "Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth - Supplementary Data", Molecular Medicine in Practice, (20100101), vol. 9, no. 8, pages 1 - 12 .
  • the present disclosure provides BRaf inhibitors of formula (I) as defined herein.
  • the present disclosure also provides compositions comprising the compounds of formula (I) and methods of treating dermatological adverse reactions induced by chemotherapy agents such as EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof using the compounds and compositions of the present disclosure.
  • the present invention relates to a compound of formula (I): wherein R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1 - methyl-1H-pyrazol-5-yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or a solvate thereof.
  • R is 3-(trifluoromethoxy)phenyl.
  • the compound of formula I is for use in inhibiting the activity of BRaf.
  • the compound has a photo-irritation factor (PIF) of less than 5.
  • PPF photo-irritation factor
  • MPE mean photo effect
  • the present invention relates also to a pharmaceutical composition, comprising: a compound of formula (I): wherein R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1 - methyl-1H-pyrazol-5-yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or a solvate thereof; and a pharmaceutically acceptable carrier or excipient.
  • R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1 - methyl-1H-pyrazol-5-yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or
  • R is 3-(trifluoromethoxy)phenyl.
  • the composition is formulated for systemic administration.
  • the composition is formulated for topical administration.
  • the composition is administered orally in the form of a tablet, a capsule, a liquid, a suspension or a powder.
  • the composition is in the form of a gel, a hydrogel, an ointment, a cream, a foam, a spray, a lotion, a liquid or a dermal patch.
  • the compound is present at a concentration of 1% w/w to 5% w/w of the total weight of the composition.
  • the compound is present at a concentration of 5% w/w to 10% w/w of the total weight of the composition.
  • the pharmaceutical composition comprises the therapeutically effective amount of the compound of formula (I), for use in treating and/or ameliorating a cutaneous adverse reaction to EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof in a subject in need thereof, and wherein the cutaneous adverse reaction is selected from acneiform rash, papulopustular rash, abnormal scalp hair growth, abnormal facial hair growth, abnormal hair growth, abnormal eyelash growth, paronychia with or without pyogenic granulomas and telangiectasia.
  • a cutaneous adverse reaction is selected from acneiform rash, papulopustular rash, abnormal scalp hair growth, abnormal facial hair growth, abnormal hair growth, abnormal eyelash growth, paronychia with or without pyogenic granulomas and telangiectasia.
  • R is 3-(trifluoromethoxy)phenyl.
  • the cutaneous adverse reaction is acneiform rash.
  • the subject is treated with an EGFR inhibitor, a PI3K inhibitor, a MEK inhibitor or a combination thereof, prior to administration of the pharmaceutical composition.
  • the EGFR inhibitor is selected from: Iressa ® (gefitinib), Tarceva ® (erlotinib), Tykerb ® (Lapatinib), Erbitux ® (cetuximab), Vectibix ® (panitumumab), Caprelsa ® (vandetanib), Portrazza ® (necitumumab), Tagrisso ® (osimertinib) and combinations thereof.
  • the PI3K inhibitor is selected from GDC-0980 (Apitolisib), GDC-0941 (Pictilisib), BAY 80-6946 (Copanlisib), BKM120 (Buparlisib), NVP-BEZ235 (Dactolisib), IPI 145 (Duvelisib), Idelalisib (GS-1101 or CAL-101), wortmannin and LY294002 and combinations thereof.
  • the MEK inhibitor is selected from Trametinib (GSK1120212), Cobimetinib (XL518), Binimetinib (MEK162), Selumetinib, PD-325901, CI-1040, PD035901, UO126, TAK-733 and combinations thereof.
  • the pharmaceutical composition for use is for topical administration.
  • the pharmaceutical composition for use is in the form of a gel, a hydrogel, an ointment, a cream, a spray, a dermal patch, a foam, a lotion or a liquid.
  • the pharmaceutical composition for use is for a systemic administration selected from enteral administration and parenteral administration.
  • the pharmaceutical composition for use is for reducing the severity or preventing the escalation of the cutaneous adverse reaction.
  • R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or a solvate thereof.
  • the compounds of present disclosure inhibit the activity of BRaf.
  • the compounds of present disclosure may have an IC50 towards BRaf of about 0.5 ⁇ 10 -8 M to about 5 ⁇ 10 -8 M, about 1 ⁇ 10 -8 M to about 5 ⁇ 10 -8 M, about 1 ⁇ 10 -8 M to about 3.5 ⁇ 10 -8 M, or about 1 ⁇ 10 -8 M to about 3 ⁇ 10 -8 M.
  • the compounds of present disclosure increase the activity of Mitogen-Activated Protein Kinases (MAPK).
  • MAPK Mitogen-Activated Protein Kinases
  • the compounds of present disclosure increase the activity of MAPK and simultaneously inhibit the activity of BRaf.
  • the activity of MAPK is determined by measuring the phosphorylation of Extracellular Signal-Regulated Kinase (ERK) and calculating a ratio of phospho-ERK to total ERK.
  • ERK Extracellular Signal-Regulated Kinase
  • the compounds of the present disclosure increase the ratio of phospho-ERK to total ERK by at least about 1.025 fold, 1.05 fold, 1.10-fold, 1.15-fold, 1.20-fold, 1.25-fold, 1.30 fold, 1.35-fold, 1.40-fold, 1.45-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 2-fold, 2.25-fold, 2.5-fold, 2.75-fold, 3-fold, 3.25-fold, 3.5-fold, 3.75-fold, 4-fold, 4.25-fold, 4.5-fold, 4.75-fold, 5-fold, 5.25-fold, 5.50-fold, 5.75-fold, 6-fold, 6.25-fold, 6.50-fold, 6.75-fold, 7-fold, 7.25-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 75-fold, 100-fold, 150-fold, or
  • the compounds of the present disclosure increase the ratio of phospho-ERK to total ERK by about 1.5-fold to about 50-fold, about 1.5-fold to about 25-fold, 1.5-fold to about 20-fold, about 1.5-fold to about 15-fold, about 2.5-fold to about 15-fold, about 2.5-fold to about 10-fold, about 3-fold to about 20-fold, about 3-fold to about 15-fold, about 4-fold to about 20-fold, about 4-fold to about 15-fold, about 4-fold to about 10-fold, about 5-fold to about 20-fold, about 5-fold to about 15-fold, including values and ranges therebetween, compared to untreated or control-treated cells.
  • the compounds of the present disclosure increase the level of phospho-ERK relative to total ERK by at least about 2.5%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, 300%, 325%, 350%, 375% 400%, 425%, 450%, 475%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1000%, 1100%, 1200%, 1300%, 1400%, 1500%, 1600%, 1700%, 1800%, 1900%, 2000%, 2250%, 2500%, 2750%, 3000%, 3250%, 3500%, 4000%, 4500%, 4750%, 5000%, 5500%, 6,000%, 6500%, 7,000%, 7500%, 8,000%, 9,000%, or 10,000%
  • the compounds of present disclosure show no phototoxicity or reduced phototoxicity.
  • the level of phototoxicity can be determined by measuring a Photo-Irritation Factor (PIF) or a Mean Photo Effect (MPE).
  • PPF Photo-Irritation Factor
  • MPE Mean Photo Effect
  • the compounds of present disclosure have a PIF of less than 5. In another aspect, the compounds of present disclosure have a PIF of less than 2.
  • the MPE can be calculated by comparing the complete concentration-response curves.
  • MPE is a weighted average of the difference in response of equivalent doses normalized by the shift in IC50.
  • MPE > 0.15 indicates phototoxicity; 0.1 ⁇ MPE ⁇ 0.15 indicates probable phototoxicity; MPE ⁇ 0.1 indicates no phototoxicity.
  • the compounds of present disclosure have a MPE of less than 0.15. In another aspect, the compounds of present disclosure have a MPE of less than 0.1.
  • compositions comprising a compound of Formula (I): wherein R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5 -yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or a solvate thereof, or a combination thereof; and a pharmaceutically acceptable carrier or excipient.
  • R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5 -yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or a solvate thereof, or
  • compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof, or a combination thereof, and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition may comprise about 1% w/w to about 5% w/w of a compound of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof, or a combination thereof, based on the total weight of the composition.
  • the pharmaceutical composition may comprise about 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, or 5% w/w, including values and ranges therebetween, of any of the compounds disclosed herein.
  • the pharmaceutical composition may comprise about 1% to about 3%, about 1% to about 4%, about 1.5% to about 5%, about 1.5% to about 4.5%, about 1.5% to 3.5%, about 1.5% to about 3%, about 2% to about 5%, about 2% to about 4.5%, about 2% to about 4%, about 2.5% to about 5%, about 2.5% to about 4.5%, about 2.5% to about 4%, about 3% to about 5%, about 3.5% to about 5% w/w, including values and ranges therebetween, of any of the compounds disclosed herein.
  • a pharmaceutical composition may comprise about 5% w/w to about 10% w/w of a compound of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof, or a combination thereof, based on the total weight of the composition.
  • the pharmaceutical composition may comprise about 5%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, or 10% w/w, including values and ranges therebetween, of any of the compounds disclosed herein.
  • the pharmaceutical composition may comprise about 5% to about 9%, about 5% to about 8.5%, about 5% to about 8%, about 5% to about 7.5%, about 5% to about 7%, about 6% to about 10%, about 6% to about 9%, about 6% to about 8.5%, about 6% to about 8%, about 7% to about 10%, about 7% to about 9.5%, about 7% to about 8.5%, about 7.5% to about 10%, about 8% to about 10% w/w, including values and ranges therebetween, of any of the compounds disclosed herein.
  • the pharmaceutical composition may comprise about 1% to about 10%, about 1% to about 8%, about 1% to about 7%, about 2% to about 8%, about 2% to about 7%, about 2% to about 6%, about 2.5% to about 7.5%, about 2.5% to about 5.5%, about 3% to about 8%, about 3% to about 7%, about 4% to about 8%, about 4% to about 7%, about 4.5% to about 7.5%, about 4.5% to about 7%, or about 4.5% to about 6.5% w/w, including values and ranges therebetween, of any of the compounds disclosed herein.
  • the pharmaceutical composition comprising any one of the compounds disclosed herein is formulated for systemic administration.
  • Systemic administration can be via enteral or parenteral route of administration.
  • systemic administration is oral administration
  • the pharmaceutical composition is formulated for oral administration (oral pharmaceutical composition).
  • an oral pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof, or a combination thereof, and a pharmaceutically acceptable carrier or excipient.
  • Oral pharmaceutical compositions of the present disclosure can be in the form of a solid dosage form or a liquid dosage form and may comprise any of the disclosed compound(s) in any of the amounts described herein.
  • the pharmaceutical composition comprising any one of the compounds disclosed herein is formulated for topical administration.
  • Topical administration comprises local application of the composition to the skin, nails, eyes, eyelashes, eyelids, and/or hair of the subject.
  • compositions for topical administration can be in the form of a gel, a hydrogel, an ointment, a cream, a foam, a spray, a lotion, a liquid, or a dermal patch and may comprise any of the disclosed compound(s) in any of the amounts described herein.
  • an oral or a topical pharmaceutical composition comprises a compound of formula: in any of the amounts disclosed herein and a pharmaceutically acceptable carrier or excipient.
  • a topical pharmaceutical composition comprising LUT014 in any of the w/w% amounts disclosed herein and a pharmaceutically acceptable carrier or excipient.
  • the topical composition comprising LUT014 may be formulated in a dosage form selected from ointment, cream, gel, hydrogel, foam, spray, lotion, liquid and dermal patch.
  • an oral pharmaceutical composition comprising LUT014 in any of the w/w% amounts disclosed herein and a pharmaceutically acceptable carrier or excipient.
  • the oral pharmaceutical composition comprising LUT014 can be in the form of a solid dosage form or a liquid dosage form.
  • Solid dosage forms for oral administration include capsules, tablets, powders, and granules.
  • the active compound is admixed with at least one inert excipient (or carrier) such as sodium citrate or dicalcium phosphate or
  • fillers or extenders for example, starches, lactose, sucrose, mannitol, and silicic acid;
  • binders for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia;
  • humectants for example, glycerol;
  • disintegrating agents for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate;
  • solution retarders for example, paraffin;
  • absorption accelerators for example, quaternary ammonium compounds;
  • wetting agents for example, cetyl alcohol and
  • An exemplary capsule dosage form may comprise soft or hard-filled gelatin capsules comprising one or more compounds of the present disclosure and excipients such as lactose or milk sugar, high molecular weight polyethylene glycols, and the like.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame seed oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • inert diluents commonly used in the art, such as water or other solvents, solubilizing
  • the liquid dosage forms can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compound, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances, and the like.
  • An exemplary liquid dosage form for oral administration may comprise a syrup comprising one or more compounds of the present disclosure and excipients like glycerol, propylene glycol and sucrose.
  • Topical compositions useful in the present disclosure may be formulated as a solution.
  • Such compositions may comprise an emollient preferably containing from about 1% to about 50% of an emollient(s).
  • emollient refers to materials used for the prevention or relief of dryness, as well as for the protection of the skin.
  • suitable emollients are known and may be used in the present disclosure. For example, Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972 ) and the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen, pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and Fragrance Assoc., Washington, D.C., 7th Edition, 1997 ) (hereinafter "ICI Handbook”) contains numerous examples of suitable materials.
  • a lotion can be made from such a solution.
  • Lotions typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s) and from about 50% to about 90% (e.g., from about 60% to about 80%) of water.
  • a cream typically comprises from about 5% to about 50% (e.g., from about 10% to about 20%) of an emollient(s) and from about 45% to about 85% (e.g., from about 50% to about 75%) of water.
  • An ointment may comprise a simple base of animal or vegetable oils or semisolid hydrocarbons.
  • An ointment may comprise from about 2% to about 10% of an emollient(s) plus from about 0.1% to about 2% of a thickening agent(s).
  • thickening agents or viscosity increasing agents useful herein can be found in Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972 ) and the ICI Handbook pp. 1693-1697.
  • the topical compositions useful in the present disclosure may be formulated as emulsions. If the carrier for a topical composition is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the carrier comprises an emulsifier(s).
  • Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are disclosed in, for example, in McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986 ), and the ICI Handbook, pp.1673-1686.
  • Lotions and creams can be formulated as emulsions.
  • Such lotions may comprise from 0.5% to about 5% of an emulsifier(s).
  • Creams may comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s); from about 20% to about 80% (e.g., from 30% to about 70%) of water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier(s).
  • the topical compositions of this disclosure can also be formulated as a gel (e.g., an aqueous, alcohol, alcohol/water, or oil gel using a suitable gelling agent(s)).
  • suitable gelling agents for aqueous gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose).
  • Suitable gelling agents for oils include, but are not limited to, hydrogenated butylene/ethylene/styrene copolymer and hydrogenated ethylene/propylene/styrene copolymer.
  • Gel compositions may comprise between about 0.1% and 5%, by weight, of such gelling agents.
  • emollients and surface active agents can be incorporated into the topical compositions, including glycerol trioleate, acetylated sucrose distearate, sorbitan trioleate, polyoxyethylene (1) monostearate, glycerol monooleate, sucrose distearate, polyethylene glycol (50) monostearate, octylphenoxypoly (ethyleneoxy) ethanol, decaglycerin penta-isostearate, sorbitan sesquioleate, hydroxylated lanolin, lanolin, triglyceryl diisostearate, polyoxyethylene (2) oleyl ether, calcium stearoyl-2-lactylate, methyl glucoside sesquistearate, sorbitan monopalmitate, methoxy polyethylene glycol-22/dodecyl glycol copolymer (Elfacos E200), polyethylene glycol-45/dodec
  • the dermatological condition is a dermatological or cutaneous adverse reactions induced by chemotherapy agents such as EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof.
  • a method for treating, ameliorating, and/or preventing a cutaneous adverse reaction of EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof in a subject in need thereof comprising administering a therapeutically effective amount of a composition comprising a compound of formula (I) wherein R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or a solvate thereof; or a combination thereof; and a pharmaceutically acceptable carrier or excipient.
  • R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl
  • compounds for use, ameliorating, and/or preventing a cutaneous adverse reaction of EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof in a subject in need thereof comprise administering a therapeutically effective amount of a composition comprising a compound of formula (I), wherein R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5 -yl, 3-(trifluoromethoxy)phenyl, or a pharmaceutically acceptable salt or a solvate thereof, or a combination thereof; and a pharmaceutically acceptable carrier or excipient.
  • R is selected from the group consisting of 3-chloro-4-fluorophenyl, 2-fluoro-4-iodophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-
  • compounds for use, ameliorating, and/or preventing a cutaneous adverse reaction of EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof in a subject in need thereof comprise administering a therapeutically effective amount of a composition comprising a combination of any of the compounds disclosed herein and a pharmaceutically acceptable carrier or excipient.
  • compounds for use, ameliorating, and/or preventing a cutaneous adverse reaction of EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof in a subject in need thereof comprise administering a therapeutically effective amount of a composition comprising a compound of formula in any of the w/w% amounts disclosed herein and a pharmaceutically acceptable carrier or excipient.
  • Dermatological or cutaneous adverse reactions induced by chemotherapy agents such as EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof include acneiform rash, papulopustular rash, abnormal scalp hair growth, abnormal facial hair growth, abnormal hair growth, abnormal eyelash growth, xerosis, pruritus, paronychia with or without pyogenic granulomas and telangiectasia.
  • chemotherapy agents such as EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof include acneiform rash, papulopustular rash, abnormal scalp hair growth, abnormal facial hair growth, abnormal hair growth, abnormal eyelash growth, xerosis, pruritus, paronychia with or without pyogenic granulomas and telangiectasia.
  • the methods described herein treat, ameliorate, and/or prevent one or more of these adverse reactions.
  • a cutaneous adverse reaction of EGFR inhibitors, PI3K inhibitors, MEK inhibitors or combinations thereof that is treated, ameliorated, and/or prevented by the compounds/compositions of the present disclosure is acneiform rash.
  • the subject is a mammal such as a human, dog, and/or cat.
  • the subject is receiving an EGFR inhibitor, PI3K inhibitor, MEK inhibitor or a combination thereof at the time of administering the compounds/compositions of the present disclosure.
  • the compounds/compositions of the present disclosure are administered to the subject prior to or after administration of an EGFR inhibitor, PI3K inhibitor, MEK inhibitor or a combination thereof.
  • methods disclosed herein comprise systemic or topical administration of a therapeutically effective amount of the compounds/compositions of the present disclosure.
  • Topical administration comprises local administration or application of any of the compositions disclosed herein to the skin, nails, eyes, eyelashes, eyelids, and/or hair of the subject.
  • topical administration comprises topically administering a composition formulated in a dosage form selected from a gel, a hydrogel, an ointment, a cream, a spray, a dermal patch, a foam, a lotion and a liquid.
  • Systemic administration comprises enteral administration or parenteral administration.
  • the systemic administration comprises oral administration.
  • oral administration comprises administration of an oral dosage form selected from tablet, capsule, liquid, suspension and powder.
  • methods disclosed herein comprise systemically or topically administering about 0.1 mg/day to about 1 mg/day of one or more compounds of the present disclosure. In some aspects, methods disclosed herein comprise systemically or topically administering about 0.1 mg/day, about 0.2 mg/day, about 0.3 mg/day, about 0.4 mg/day, about 0.5 mg/day, about 0.6 mg/day, about 0.7 mg/day, about 0.8 mg/day, about 0.9 mg/day, or about 1 mg/day, including values and ranges therebetween, of one or more compounds of the present disclosure.
  • methods disclosed herein comprise systemically or topically administering about 0.1 mg/day to about 0.5 mg/day, about 0.2 mg/day to about 0.8 mg/day, about 0.2 mg/day to about 0.5 mg/day, or about 0.5 mg/day to about 1 mg/day, including values and ranges therebetween, of one or more compounds of the present disclosure.
  • methods disclosed herein comprise systemically or topically administering about 1 mg/day to about 5 mg/day of one or more compounds of the present disclosure. In some aspects, methods disclosed herein comprise systemically or topically administering about 1 mg/day, 1.5 mg/day, 2 mg/day, 2.5 mg/day, 3 mg/day, 3.5 mg/day, 4 mg/day, 4.5 mg/day, or 5 mg/day, including values and ranges therebetween, of one or more compounds of the present disclosure.
  • methods disclosed herein comprise systemically or topically administering about 5 mg/day to about 10 mg/day of one or more compounds of the present disclosure. In some aspects, methods disclosed herein comprise systemically or topically administering about 5 mg/day, about 5.5 mg/day, about 6 mg/day, about 6.5 mg/day, about 7 mg/day, about 7.5 mg/day, about 8 mg/day, about 8.5 mg/day, about 9 mg/day, about 9.5 mg/day, or about 10 mg/day, including values and ranges therebetween, of one or more compounds of the present disclosure.
  • methods disclosed herein comprise systemically or topically administering about 1 mg/day to about 10 mg/day, about 1 mg/day to about 8 mg/day, about 2 mg/day to about 8 mg/day, about 2.5 mg/day to about 7.5 mg/day, about 3 mg/day to about 8 mg/day, about 3 mg/day to about 6 mg/day, or about 4 mg/day to about 8 mg/day, including values and ranges therebetween, of one or more compounds of the present disclosure.
  • the amount of the compound administered depends on the nature of the compound, the mode of administration, and/or the severity of the cutaneous reaction.
  • the therapeutically effective amount that need to be administered to a patient can be determined by dose-ranging clinical studies known in the art.
  • an EGFR inhibitor is selected from Iressa (gefitinib), Tarceva (erlotinib), Tykerb (Lapatinib), Erbitux (cetuximab), Vectibix (panitumumab), Caprelsa (vandetanib), Portrazza (necitumumab), Tagrisso (osimertinib) and combinations thereof.
  • a PI3K inhibitor is selected from GDC-0980 (Apitolisib), GDC-0941 (Pictilisib), BAY 80-6946 (Copanlisib), BKM120 (Puparlisib), NVP-BEZ235 (Dactolisib), IPI 145 (Duvelisib), Idelalisib (GS-1101 or CAL-101), wortmannin, LY294002 and combinations thereof.
  • a MEK inhibitor is selected from Trametinib (GSK1120212), Cobimetinib (XL518), Binimetinib (MEK162), Selumetinib, PD-325901, CI-1040, PD035901, UO126, TAK-733, and combinations thereof.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 4 to grade 3, 2, 1, or 0, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 3 to grade 2, 1, or 0, as defined by NCI-CTCAE version 4.0.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 2 to grade 1 or 0, as defined by NCI-CTCAE version 4.0.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 1 to grade 0, as defined by NCI-CTCAE version 4.0.
  • the methods disclosed herein prevent, partially or completely, the development of cutaneous adverse reactions.
  • the methods disclosed herein prevent, partially or completely, the development of grade 4, grade 3, grade 2, or grade 1 of the cutaneous adverse reactions, as defined by NCI-CTCAE version 4.0.
  • the methods disclosed herein prevent the escalation of the cutaneous adverse reaction.
  • the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 0 to grade 1, 2, 3, or 4, as defined by NCI-CTCAE version 4.0.
  • the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 1 to grade 2, 3, or 4, as defined by NCI-CTCAE version 4.0.
  • the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 2 to grade 3 or 4, as defined by NCI-CTCAE version 4.0.
  • the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 3 to grade 4, as defined by NCI-CTCAE version 4.0.
  • Table 2 Adverse Event Grade 1 Grade 2 Grade 3 Grade 4 Papulopustular eruption Grading individually or face, scalp, chest or back) 1A Papules or pustules ⁇ 5 OR 1 area of erythema or edema ⁇ 1 cm n size 1B Papules or pustules ⁇ 5; OR 1 area of serythema or edema ⁇ 1cm in size AND pain or pruritus 2A Papules or pustules 6-20; OR 2-5 areas of erylhema or edema ⁇ 1cm in size 2B Papules or pustules 6-20: OR 2-5 areas of erythema or edema ⁇ 1cm in AND pain, pruritus, or effect on emotions or functioning 3A Papules or pustules >20; OR more than 5 areas of erythema
  • Camouflage 2A Hair loss associated with marked increase in shedding and 50%-74% loss compared to normal for that individual. Hair loss is apparent to others, may be difficult to camouflage with change in hair style and may require hairpiece 2B: Marked loss of at least 75% hair compared to normal for that individual with inability to camouflage except with a full wig OR new cicatricial hair loss documented by biopsy that covers at least 5% scalp surface area. May impact on functoning in social, personal or professional situtions - Hair Changes: disruption of normal hair growth (specify): Facial hair (diffuse.
  • 2A Increase in ength, thickness and/or density of hairs that is very noticeable and requires regular shaving or removal of hairs in order to camouflage. May cause mild symptoms related to hair overgrowth.
  • 2B Marked increase in hair density, thickness and/or length of hair that requires either frequent shaving or destruction of the hair to camouflage May cause symptoms related to hair overgrowth Without hair removal, inability to function normally in social, personal or professional situations Flushing 1A Face OR chest, asymptomatic, transient 1B. Any location, asymptomatic, permanent 2A Symtomatic on face, or chest, transient 2B. Symptomatic on face, or chest, permanent 3A Face and chest, transient, symptomatic 3B.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 4 to grade 3B, 3A, 2B, 2A, 1B, or 1A, as defined by Lacouture grading scale.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 3B to grade 3A, 2B, 2A, 1B, or 1A, as defined by Lacouture grading scale.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 3A to grade 2B, 2A, 1B, or 1A, as defined by Lacouture grading scale.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 2B to grade 2A, 1B, or 1A, as defined by Lacouture grading scale.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 2A to grade 1B or 1A, as defined by Lacouture grading scale.
  • the methods disclosed herein reduce the severity of the cutaneous adverse reactions from grade 1B to grade 1A, as defined by Lacouture grading scale.
  • the methods disclosed herein prevent, partially or completely, the development of grade 4, grade 3B, grade 3A, grade 2B, grade 2A, grade 1B, or grade 1A of the cutaneous adverse reactions, as defined by Lacouture grading scale.
  • the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 1A to grade 1B, 2A, 2B, 3A, 3B or 4, as defined by Lacouture grading scale. In another aspect, the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 1B to grade 2A, 2B, 3A, 3B or 4, as defined by Lacouture grading scale. In one aspect, the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 2A to grade 2B, 3A, 3B or 4, as defined by Lacouture grading scale.
  • the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 2B to grade 3A, 3B or 4, as defined by Lacouture grading scale. In one aspect, the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 3A to grade 3B or 4, as defined by Lacouture grading scale. In one aspect, the methods disclosed herein prevent the escalation of the cutaneous adverse reaction from grade 3B to grade 4, as defined by Lacouture grading scale.
  • the known compound C-1 was prepared according to the synthetic procedure detailed in Smith A.L. et al., J. Med. Chem. 2009,52, 6189-6192 .
  • reaction mixture was cooled to 20°C and poured into 5 N NaOH aqueous (50 mL) and stirred for 5 min, filtered and the aqueous phase was extracted with dichloromethane (50 mL, 20 mL). The combined organic phase was dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to give compound 3B (2.30 g, crude) as a brown solid, which was used for next step without further purification.
  • reaction mixture was quenched with drop-wise addition of ice-water (2 mL) at 0 °C resulting in a light orange solution containing a white solid in suspension.
  • the mixture was concentrated to give a yellow solid which was suspended in ethyl acetate (50 mL), dried with Na 2 SO 4 , filtered through a plug of Celite to give a yellow solution and was concentrated in vacuum.
  • the residue was washed with methyl tert-butyl ether (20 mL), filtered to afford the filter cake and the filter cake was dried in vacuum to afford compound 4B (1.10 g, 1.99 mmol, 59.6% yield) as light-yellow solid.
  • the filter liquor was extracted with ethyl acetate (10 mL, 6 mL). The combined organic phase was washed with brine (20 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: YMC-Actus Triart C18 100 ⁇ 30 mm ⁇ 5 um; mobile phase: [water (10 mM NH 4 HCO 3 )-ACN]; B%: 40%-60%, 12 min) to afford LUT013 (150 mg, 295 umol, 69.6% yield, 99.4% purity) as yellow solid.
  • Example 3 discloses a process for the synthesis of the LUT014 compound at laboratory scale.
  • the improved scaled-up synthetic process produced 4,015 Kg LUT014, a very large scale-up, as compared to the above laboratory scale process of Example 3, which resulted in 150 mg.
  • the flow diagram in FIG. 6 depicts the improved scaled-up process for the preparation of LUT014 (C17071479-F), its stages, amounts, yields and purities of the intermediates and of the LUT014 (C17071479-F) product.
  • This Example validates the improved scaled-up synthesis of the LUT014 compound at kilogram scale in a multi-stage process followed by purification by crystallization yielding a purified product of 99.3% purity.
  • reaction mixture was cooled to 20 °C and poured to 5 N NaOH aqueous (20 mL) and stirred for 3 min, filtered and the filtrate was extracted with dichloromethane (20 mL, 15 mL). The combined organic phase was dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to afford compound 3F (2.20 g, crude) as red solid, which was used for next step without further purification.
  • reaction mixture was quenched with dropwise addition of ice-water (2 mL) at 0 °C while resulting in a light orange solution containing a white solid in suspension.
  • the mixture was concentrated to give a yellow solid which was suspended in ethyl acetate (50 mL), dried with Na 2 SO 4 , filtered through a plug of Celite to give a yellow solution and was concentrated in vacuum.
  • the residue was washed with methyl tert-butyl ether (20 mL), filtered to afford the filter cake and filter cake was dried in vacuum to give compound 4F (1.10 g, 1.64 mmol, 49.0% yield) as a light-yellow solid.
  • the solid was purified by prep-HPLC (column: YMC-Actus Triart C18 100 ⁇ 30mm ⁇ 5um; liquid phase: [A-10mM NH4HCO 3 in H 2 O; B-ACN]B%: 50%-95%,12min]) to give LUT017 (150 mg, 269 umol, 11.3% yield, 98.0% purity) as a yellow solid.
  • reaction mixture was cooled to 20 °C and poured to 5 N NaOH aqueous (20 mL) and stirred for 5 min, filtered and the filtrate was extracted with dichloromethane (20 mL, 15 mL). The combined organic phase was dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to afford compound 3H (3.80 g, crude) as a red solid, which was used for next step without further purification.
  • reaction mixture was quenched with dropwise addition of ice-water (2.0 mL) at 0 °C while resulting in a light orange solution containing a white solid in suspension.
  • the mixture was concentrated to give a yellow solid which was suspended in ethyl acetate (50 mL), dried with Na 2 SO 4 , filtered through a plug of Celite to give a yellow solution and was concentrated in vacuum.
  • the residue was washed with methyl tert-butyl ether (20 mL), filtered to afford the filter cake and filter cake was dried in vacuum to afford compound 4H (2.30 g, crude) as a brown solid.
  • the solid was purified by prep-HPLC (column: YMC-Actus Triart C18 100 ⁇ 30mm ⁇ 5um; liquid phase: [A-10mM NH 4 HCO 3 in H 2 O; B-ACN]B%: 25%-55%,12min] to give LUT020 (85.0 mg, 159 umol, 4.83% yield, 98.0% purity) as a yellow solid.
  • the BRaf inhibitory activity of the compound of formula I, where R is 3-(trifluoromethoxy)phenyl (LUT014) and Vemurafenib, a known inhibitor of BRAF containing V600E mutation was tested on wild-type BRaf and BRAF containing V600E mutation.
  • LUT014 and Vemurafenib were tested in 10-dose IC50 mode with a 3-fold serial dilution starting at 10 ⁇ M.
  • Control Compound, GW5074 was tested in 10-dose IC50 mode with 3-fold serial dilution starting at 20 ⁇ M. Reactions were carried out at 10 ⁇ M ATP.
  • keratinocytes is likely the site of the cutaneous side-effects, and the inhibition of EGFR and/or its downstream effectors (MAPK, MEK, PI3K, and the like) in keratinocytes is likely the mechanism underlying this side effect.
  • MAPK EGFR and/or its downstream effectors
  • PI3K PI3K
  • Human normal keratinocyte cells HEKa were purchased from Gibco Rhenium and seeded in 10 cm dishes (300,000 cells/dish) and incubated overnight at 37°C, 5% CO 2 . Next morning, the medium was replaced to a starvation medium for 2 hours and then the cells were treated for 2 additional hours with the test compounds. Post incubation, the cells were lyzed with RIPA and the protein extracts were analyzed by western blot for Phospho-ERK and total ERK. Untreated cells and 0.1% DMSO treated cells were used as negative control. HKGS growth factors was used as a positive control.
  • the HRP was then inactivated by incubating the membranes for 1 hour with 0.5% sodium azide Following washes and ECL exposure in order to ensure absence of signal, the membranes were re-blocked for 15min with TBST/ 5% skimmed milk and then incubated with Rabbit anti total ERK2 (1:500 in TBST 5% BSA, ON at 4°C), goat anti Rabbit HRP (1: 5,000 in TBST 5% BSA, 1-hour RT) and finally exposed using the SuperSignal West Pico Chemiluminescent Substrate. The films were scanned and the signal were quantified using ImageJ software. The results were calculated as Phospho-ERK/total ERK.
  • FIG. 1A shows Phospho-ERK (upper panel) and total ERK (lower panel) upon treatment with 0.3 ⁇ M of the test compounds.
  • FIG. 1B shows the densitometric analysis of blots in FIG. 1A based on the calculation of Phospho-ERK/total ERK ratio.
  • FIG. 1C shows Phospho-ERK (upper panel) and total ERK (lower panel) upon treatment with 1 ⁇ M of the test compounds.
  • FIG. 1D shows the densitometric analysis of blots in FIG. 1C based on the calculation of Phospho-ERK/total ERK ratio.
  • HEKa cells were treated with LUT012, LUT016, and the known compounds - Vemurafenib and C-1 (old batch and new batch) at 0.3 ⁇ M and 1( ⁇ M as described in Example 11 and the Western blot analysis of HEKa cell lysates was carried out.
  • HKGS growth factors was used as a positive control.
  • Compound C-1 has the following structure:
  • FIG. 2A shows Phospho-ERK (upper panel) and total ERK (lower panel) upon treatment with 0.3 ⁇ M of the test compounds.
  • FIG. 2B shows the densitometric analysis of blots in FIG. 2A based on the calculation of Phospho-ERK/total ERK ratio.
  • FIG. 2C shows Phospho-ERK (upper panel) and total ERK (lower panel) upon treatment with 1 ⁇ M of the test compounds.
  • FIG. 2D shows the densitometric analysis of blots in FIG. 2C based on the calculation of Phospho-ERK/total ERK ratio.
  • FIG. 3A shows Phospho-ERK (upper panel) and total ERK (lower panel) upon treatment with 0.3 ⁇ M of the test compounds.
  • FIG. 3B shows Phospho-ERK (upper panel) and total ERK (lower panel) upon treatment with 1 ⁇ M of the test compounds.
  • FIG. 3C shows the densitometric analysis of blots in FIGs. 3A and 3B based on the calculation of Phospho-ERK/total ERK ratio.
  • FIG. 4A shows Phospho-ERK (upper panel) and total ERK (lower panel) upon treatment with 0.003 ⁇ M, 0.03 ⁇ M, and 0.3 ⁇ M of the test compounds.
  • FIG. 4B shows the densitometric analysis of blots in FIG. 4A based on the calculation of Phospho-ERK/total ERK ratio.
  • the cells were seeded in starvation medium at 5000 cells/well in a 96 wells plate for 24 hours at 37°C, 5% CO 2 .
  • the tested compounds were added at different concentrations ranging from 0.002 ⁇ M to 10 ⁇ M.
  • the controls were untreated cells and vehicle of 0.1% DMSO.
  • the cells were incubated at 37°C, 5% CO 2 , for 72 hours and then the proliferation was tested using the ATPlite proliferation kit (Perkin-Elmer). Each result represents an average of 6 wells. The results are presented as the percent of over-proliferation compared to the DMSO control. See FIG. 5 .
  • DMSO concentration of the compounds that provided the highest proliferation was compared to DMSO.
  • DMSO was calculated as 100%. After 72 hours, % proliferation compared to the DMSO control induced by C-1 was 30%, LUT013 was 173%, LUT014 was 116%, LUT015 was 29%, LUT016 was 110%, LUT017 was 174%, LUT012 was 20%, LUT019 was 7%, and LUT020 was 12%.
  • Vemurafenib showed 12% proliferation compared to DMSO.
  • Certain BRaf inhibitors are known to exhibit photo-toxicity. Therefore, the compounds of the present disclosure were screened for phototoxicity using the 3T3 natural red uptake assay.
  • BALB/c-3T3 mouse fibroblasts (originally obtained from ATCC) were seeded in 96-well plates at 12,000 cells per well, and grown for 24 hr.
  • Test compounds and the positive control (chlorpromazine) were solubilized and serially diluted in DMSO.
  • the negative control (histidine) was solubilized and diluted in HBSS.
  • a dilution for all test articles was then made into HBSS at the final testing concentrations.
  • the growth medium was removed from the plates and replaced with test agent dilution. Six replicates were used for each concentration.
  • Neutral Red staining medium was removed and fresh medium containing 25 ⁇ g/mL of Neutral Red (Sigma) was added. After three hours incubation, the cells were washed with PBS, and the cellular dye was solubilized with 1% acetic acid in 50% ethanol. Cellular Neutral Red was measured by its absorbance at 540 nm.
  • PPF Photo-Irritation Factor
  • PIF > 5 indicates phototoxicity; 2 ⁇ PIF ⁇ 5 indicates probable phototoxicity; PIF ⁇ 2 indicates no phototoxicity
  • MPE Mean Photo Effect
  • HEKa cells were treated with LUT014 and EGFR inhibitors, erlotinib and cetuximab, as described in Example 11.
  • HKGS was used as a positive control.
  • the effect of LUT014 and EGFR inhibitors on phospho-ERK was measured by Western blot as described in Example 11.
  • FIG. 7 and Table 6 shows the results of the effect of LUT014 on Phospho-ERK following administration of EGFR inhibitors.
  • Table 6 The effect of LUT014 and EGFRI on phospho-ERK Gel #3 phospho ERK Total ERK phospho/tot al ratio % of control DMSO (3.75 ⁇ l) 539.971 7316.397 0.07 100.0 HKGS 9391.983 7094.569 1.32 1793.7 HKGS+Erl otinib+DM SO 7790.296 9117.004 0.85 1157.8 HKGS+Erl otinib+LU T014 10848.175 7696.983 1.41 1909.7 HKGS+Cet uximab+D MSO 6291.861 8346.569 0.75 1021.4 HKGS+Cet uximab+L UT014 11594.983 8095.397 1.43 1940.7
  • LUT014 increased phospho-ERK by 200-800% compared to the DMSO treated cells.
  • Erlotinib decreased phospho ERK compared to HKGS treated cells.
  • LUT014 increased phospho-ERK when added to cells treated with Erlotinib.
  • LUT014 increased phospho-ERK when added to cells treated with cetuximab.
  • the maximum accumulated level of LUT014 observed in the receptor solution after 24 hours was less than 2 ng/mL.
  • LUT014 Dermal administration of LUT014 was well tolerated in minipigs at levels of 5 mg/kg/day for up to 6 days.
  • LUT014 is classified as non-phototoxic (3T3 NRU) Table 7 - Toxicity Studies Study Results DRF oral in Wistar Rats Oral administration of Lut014, for 7 days in the Wistar rat at dose levels of 250,500 and 1000 mg/kg/day did not result in mortality MTD Dermal Minipigs Dermal administration of LUT014 was well tolerated in minipigs at levels of 5 mg/kg/day for up to 6 days. Sensitization GP The test article is not a dermal sensitizer In vitro Ames test Lut014is not mutagenic in the Salmonella typhimurium reverse mutation assay and in the Escherichia coli reverse mutation assay. 20145601- BCOP Lut014induced an IVIS ⁇ 3, no classification is required for eye irritation or serious eye damage 3T3 NRU Lut014is classified as non-phototoxic
  • Colorectal cancer patients receiving EGFR inhibitors who have developed acneiform lesions are colorectal cancer patients receiving EGFR inhibitors who have developed acneiform lesions.
  • MTD maximum tolerated dose
  • Enrollment will initially occur in cohorts of three subjects in a conventional 3+3 escalating dose design. Patients receiving EGFR inhibitors and who have developed grade 1 or 2 acneiform lesions will be treated with LUT014 for 4 weeks. The LUT014 gel will be applied each morning after bathing or showering. Application will be to the face and, the upper portion of the anterior and posterior chest. A thin layer of the gel will be applied.
  • the second cohort will begin.
  • patients will again have LUT014 applied to their face, plus their upper anterior and posterior chest on a daily basis after bathing for 4 weeks.
  • a third cohort of 3 patients, or 6 patients if this third cohort goes to 6 patients will be treated.
  • These patients will also have LUT014 applied over their face, anterior and posterior chest on a daily basis after bathing for 4 weeks
  • the MTD is defined as the highest dosing concentration of LUT014 at which fewer than two (of a cohort of up to six) subjects experience a DLT.
  • Determination of a DLT will require that the Grade 3 or greater toxicity occur and be determined to be possibly, probably or definitely related to the study drug by an independent safety review committee.
  • LUT014 Following completion of the dose escalation phase of the study, up to 60 patients will be enrolled and randomized to have either LUT014 at the MTD or a smaller dose chosen by the sponsor or will be treated with an identical appearing vehicle. The LUT014 or vehicle will be applied to their skin over all areas with evidence of acneiform lesions. Patients will be treated for 4 weeks.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
EP18841422.1A 2017-07-29 2018-07-26 Novel braf inhibitors and use thereof for treatment of cutaneous reactions Active EP3661515B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HRP20220609TT HRP20220609T1 (hr) 2017-07-29 2018-07-26 Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija
SI201830670T SI3661515T1 (sl) 2017-07-29 2018-07-26 Novi BRaf inhibitorji in njihova uporaba za zadravljenje kožnih reakcij

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538675P 2017-07-29 2017-07-29
PCT/IL2018/050836 WO2019026065A2 (en) 2017-07-29 2018-07-26 NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS

Publications (3)

Publication Number Publication Date
EP3661515A2 EP3661515A2 (en) 2020-06-10
EP3661515A4 EP3661515A4 (en) 2021-01-06
EP3661515B1 true EP3661515B1 (en) 2022-02-23

Family

ID=65233550

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18841422.1A Active EP3661515B1 (en) 2017-07-29 2018-07-26 Novel braf inhibitors and use thereof for treatment of cutaneous reactions

Country Status (15)

Country Link
US (3) US10927112B2 (sl)
EP (1) EP3661515B1 (sl)
JP (1) JP6912667B2 (sl)
KR (1) KR102328351B1 (sl)
CN (1) CN111132680B (sl)
AU (1) AU2018311538B2 (sl)
BR (1) BR112020001935A2 (sl)
CA (1) CA3070542C (sl)
DK (1) DK3661515T3 (sl)
ES (1) ES2908602T3 (sl)
HR (1) HRP20220609T1 (sl)
IL (1) IL272312B (sl)
SI (1) SI3661515T1 (sl)
WO (1) WO2019026065A2 (sl)
ZA (1) ZA202000354B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3072200A1 (en) * 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor
HUE063091T2 (hu) 2019-02-12 2024-01-28 Lutris Pharma Ltd Topikális BRaf inhibitor készítmények alkalmazása besugárzási dermatitis kezelésére
CN116669739A (zh) * 2020-12-24 2023-08-29 鲁特里斯制药有限公司 用于治疗egfr下游效应物诱导的反应的局部braf抑制剂组合物
WO2023275620A2 (en) * 2021-07-02 2023-01-05 Lutris Pharma Ltd. Use of isoquinoline-1,5-diamines for wound healing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2008153947A2 (en) * 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
TWI611053B (zh) * 2012-02-27 2018-01-11 曾宇鳳 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
BR112015028845A2 (pt) * 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
WO2017154001A1 (en) * 2016-03-10 2017-09-14 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions

Also Published As

Publication number Publication date
US10927112B2 (en) 2021-02-23
CN111132680B (zh) 2022-02-08
EP3661515A2 (en) 2020-06-10
JP6912667B2 (ja) 2021-08-04
RU2020108782A3 (sl) 2021-09-02
US20210070757A1 (en) 2021-03-11
IL272312A (en) 2020-03-31
AU2018311538A1 (en) 2020-02-13
ZA202000354B (en) 2024-01-31
US20220274988A1 (en) 2022-09-01
BR112020001935A2 (pt) 2020-07-28
ES2908602T3 (es) 2022-05-03
KR102328351B1 (ko) 2021-11-19
DK3661515T3 (da) 2022-04-19
US11339163B2 (en) 2022-05-24
IL272312B (en) 2021-06-30
EP3661515A4 (en) 2021-01-06
KR20200035990A (ko) 2020-04-06
JP2020528933A (ja) 2020-10-01
WO2019026065A3 (en) 2019-08-01
US20190389862A1 (en) 2019-12-26
SI3661515T1 (sl) 2022-06-30
WO2019026065A2 (en) 2019-02-07
HRP20220609T1 (hr) 2022-06-24
AU2018311538B2 (en) 2021-03-25
CA3070542C (en) 2021-05-18
CA3070542A1 (en) 2019-02-07
RU2020108782A (ru) 2021-09-02
CN111132680A (zh) 2020-05-08

Similar Documents

Publication Publication Date Title
US10927112B2 (en) BRaf inhibitors and use thereof for treatment of cutaneous reactions
CN105792823B (zh) 治疗恶性肿瘤的药物组合
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
AU2024204716A1 (en) Treatment of alopecia areata
JPH10279480A (ja) 皮膚組織障害の予防・治療剤
RU2457826C2 (ru) Профилактическое или терапевтическое средство от алопеции
CN109876000A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
JP2019519573A (ja) がんを処置するための方法
RU2779185C2 (ru) Новые ингибиторы braf и их применение для лечения кожных реакций
JPWO2006041120A1 (ja) 医薬組成物
EP4166140A1 (en) Prophylactic or therapeutic agent for porphyria
TWI308148B (en) Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component
WO2004082683A1 (ja) 慢性皮膚疾患の治療および／または予防剤
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
JP2008019252A (ja) 色素沈着症の予防または治療用医薬組成物
CA3203021A1 (en) Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions
JP6553961B2 (ja) 美白剤
WO2013035997A2 (en) Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt
WO2006082834A1 (ja) ケラチノサイト増殖に起因する疾患の予防・治療剤
WO2011090357A2 (ko) 신규한 바이아릴아미드 유도체 및 이를 유효성분으로 함유하는 조성물

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20220609

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200217

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201207

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 473/00 20060101ALI20201201BHEP

Ipc: A61K 31/52 20060101AFI20201201BHEP

Ipc: A61P 17/00 20060101ALI20201201BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210503

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20211214

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1469909

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018031387

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20220411

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2908602

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220503

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20220609

Country of ref document: HR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1469909

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220623

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220523

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220524

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220609

Country of ref document: HR

Payment date: 20220721

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018031387

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20221124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220726

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220609

Country of ref document: HR

Payment date: 20230720

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230724

Year of fee payment: 6

Ref country code: ES

Payment date: 20230927

Year of fee payment: 6

Ref country code: CH

Payment date: 20230801

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20230713

Year of fee payment: 6

Ref country code: SE

Payment date: 20230719

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20180726

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220609

Country of ref document: HR

Payment date: 20240718

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240719

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220223

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240719

Year of fee payment: 7

Ref country code: IE

Payment date: 20240722

Year of fee payment: 7

Ref country code: HR

Payment date: 20240718

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240726

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240725

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240719

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240730

Year of fee payment: 7